Insights

Marwood presents its proprietary analytics tool for reimbursement claims analysis through a case study of the outpatient orthopedics space in North Carolina. Deb Frier, Kate Gibson, and Mark Slomiany explores payor mix, rate trends, and geographic variability in reimbursement at the intra-state level.

Advances in genetics and a better understanding of the immune system have cracked open the door on the potential of animal-to-human transplants. Marwood’s Stephen Williams, Ph.D. and E. Daley Smith explore xenotransplant technology, early clinical testing, and the regulatory outlook for the procedure.

Marwood’s Mark Slomiany explores the opportunities and trends which labor cost-sensitivity may facilitate in healthcare.

Growth in the substance use disorder (SUD) treatment space has brought significant investor interest. Herein, Mark Slomiany and Deb Frier address future tailwinds and challenges to the industry.

Marwood’s Mark Slomiany addresses the growing orphan drug affordability challenge to payors and emerging countermeasures to mitigate their impact. 

In-home HRAs have seen increased attention over the last year, both in their importance to MA plans, as well as potential regulatory concerns. Marwood’s Joseph Mercer examines policy considerations for deals like CVS Health and Signify Health, in light of Congressional and CMS views on in-home HRAs and potential risk adjustment reform, Medicare trust fund solvency fixes, and increased antitrust activity by FTC and DOJ.

Pharma hub services continue to expand with the rise of specialty drugs. Herein, Mark Slomiany addresses their features, transactional trends and regulatory considerations in the patient assistance ecosystem.